Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer (ICEBERG 1)
This study is ongoing, but not recruiting participants.
First Posted: June 29, 2007
Last Update Posted: August 30, 2017
KuDOS Pharmaceuticals Limited
Information provided by (Responsible Party):